NCT04201873View on ClinicalTrials.gov

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

January 8, 2020

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions

Recurrent Glioblastoma

Interventions

BIOLOGICAL

Dendritic Cell Tumor Cell Lysate Vaccine

Given ID

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Placebo Administration

Given IV

DRUG

Poly ICLC

Given IM

Trial Locations (1)

90095

Quan, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Phase One Foundation

OTHER

collaborator

Oncovir, Inc.

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER